April 27, 2018
The National Institute of Health has awarded Lariat Biosciences entrance into the I-Corps™ program to establish a robust commercialization strategy for our RVE™ technology.
June 30, 2017
The National Cancer Institute at the NIH has awarded Lariat Biosciences a Phase I SBIR to extend our portfolio of biomarkers for cancer beyond single nucleotide polymorphisms and to include variable mutations refered to as small insertions and delections.
June 28, 2017
Extending our efforts on multiplexed detection of single nucleotide polymorphisms, Lariat Biosciences has been awarded a MassRamp grant from the Massachusetts Life Sciences Center.
April 8, 2015
The National Cancer Institute at the NIH has awarded Lariat Biosciences a Phase I SBIR for developing an ultrasensitive and specific liquid biopsy that is based on detecting single nucleotide polymorphisms within circulating free DNA in the bloodstream.
March 1, 2013
Lariat Biosciences has entered the North Shore Innoventures biotechnology incubator after passing a vigorous and comprehensive review of our business strategy.